Arimoclomol: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Arimoclomol. Educational only — not medical advice.
Labeled uses
MIPLYFFA is indicated for use in combination with miglustat for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in adult and pediatric patients 2 years of age and older.
Source: FDA labeling via NIH DailyMed (set 5feffc0e…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.